EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

An S100A8/A9 Neutralizing Antibody Potently Ameliorates Contact Hypersensitivity and Atopic Dermatitis Symptoms

Yuma Gohara, Rie Kinoshita, Nahoko Tomonobu, Fan Jiang, Yukiko Matsunaga, Yuki Hashimoto, Tomoko Honjo, Ken-Ichi Yamamoto, Hitoshi Murata, Toshiki Ochi, Ni Luh Gede Yoni Komalasari, Akira Yamauchi und 12 weitere

Journal of Investigative Dermatology · 2025

DOI: 10.1016/j.jid.2025.01.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Investigative Dermatology, 2025. Verfasst von Yuma Gohara und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Biology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. Hauptthemen laut MEDLINE: Calgranulin B, Calgranulin A, Dermatitis, Atopic, Antibodies, Neutralizing. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Obayashi Foundation, Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Contact hypersensitivity and atopic dermatitis are pervasive inflammatory skin diseases with similar symptoms, and their global prevalence is steadily increasing. Many compounds and biotics have been developed to target molecules critical to the etiology or pathogenesis of contact hypersensitivity and atopic dermatitis. However, these molecules are sometimes ineffective or lose their potency during the therapeutic course. Therefore, innovative medicines are still needed for the treatment of intractable cases. We focused on S100A8/A9, a heterodimer complex of S100A8 and S100A9 that is abundant in the extracellular milieu of inflammatory skin lesions. Although S100A8/A9 is primarily recognized as a diagnostic marker protein, we have previously shown that it also plays a crucial role in contact hypersensitivity and atopic dermatitis progression. This insight inspired us to develop its inhibitory antibody, leading to the ground-breaking Ab45. In this study, we demonstrated that Ab45 effectively prevented disease symptoms in various models and that its disease-ameliorating activity likely involved the downregulation of several disease-relevant molecules, including Il-23a, Il-36g, S100a8, and S100a9. We also created a humanized version of Ab45, HuAb45, which exhibited similar effectiveness. These antibodies show great promise for the treatment of contact hypersensitivity and atopic dermatitis and possibly for other inflammatory skin diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Calgranulin BCalgranulin ADermatitis, AtopicAntibodies, NeutralizingDermatitis, ContactHumansAnimalsMiceDisease Models, AnimalFemale

Stichwörter der Autor:innen

Atopic dermatitisContact hypersensitivityHumanized antibodyInflammationS100 protein

Substanzen

Calgranulin BCalgranulin AAntibodies, Neutralizing

Autor:innen und Institutionen

  • Department of Cell Biology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
  • Department of Dermatology, Toho University Graduate School of Medicine, Tokyo, Japan.
  • Department of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama, Japan.
  • Department of Cell Biology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and P…
  • Faculty of Medicine, Udayana University, Denpasar, Indonesia.
  • Department of Biochemistry, Kawasaki Medical School, Kurashiki, Japan.

Förderung

  • Obayashi Foundation
  • Japan Society for the Promotion of Science
  • Japan Agency for Medical Research and Development

Zitieren

APA

Gohara, Y., Kinoshita, R., Tomonobu, N., Jiang, F., Matsunaga, Y., Hashimoto, Y., Honjo, T., Yamamoto, K. I., Murata, H., Ochi, T., Komalasari, N. L. G. Y., Yamauchi, A., Kuribayashi, F., Sakaguchi, Y., Futami, J., Inoue, Y., Kondo, E., Toyooka, S., Morizane, S., …, & Sakaguchi, M. (2025). An S100A8/A9 Neutralizing Antibody Potently Ameliorates Contact Hypersensitivity and Atopic Dermatitis Symptoms. Journal of Investigative Dermatology. https://doi.org/10.1016/j.jid.2025.01.007

Vancouver

Gohara Y, Kinoshita R, Tomonobu N, Jiang F, Matsunaga Y, Hashimoto Y, et al. An S100A8/A9 Neutralizing Antibody Potently Ameliorates Contact Hypersensitivity and Atopic Dermatitis Symptoms. Journal of Investigative Dermatology. 2025. doi:10.1016/j.jid.2025.01.007

BibTeX
@article{Gohara2025,
  author = {Gohara, Yuma and Kinoshita, Rie and Tomonobu, Nahoko and Jiang, Fan and Matsunaga, Yukiko and Hashimoto, Yuki and Honjo, Tomoko and Yamamoto, Ken-Ichi and Murata, Hitoshi and Ochi, Toshiki and Komalasari, Ni Luh Gede Yoni and Yamauchi, Akira and Kuribayashi, Futoshi and Sakaguchi, Yoshihiko and Futami, Junichiro and Inoue, Yusuke and Kondo, Eisaku and Toyooka, Shinichi and Morizane, Shin and Ishiko, Akira and Morita, Shigeru and Sagayama, Kazumi and Nakao, Kenichiro and Sakaguchi, Masakiyo},
  title = {An S100A8/A9 Neutralizing Antibody Potently Ameliorates Contact Hypersensitivity and Atopic Dermatitis Symptoms},
  journal = {Journal of Investigative Dermatology},
  year = {2025},
  doi = {10.1016/j.jid.2025.01.007}
}
Kostenlos starten →